Representative Jennifer Dailey-Provost proposes the following substitute bill:


1     
MEDICAL CANNABIS MODIFICATIONS

2     
2020 GENERAL SESSION

3     
STATE OF UTAH

4     
Chief Sponsor: Jennifer Dailey-Provost

5     
Senate Sponsor: Evan J. Vickers

6     

7     LONG TITLE
8     General Description:
9          This bill amends provisions regarding medical cannabis.
10     Highlighted Provisions:
11          This bill:
12          ▸     defines terms;
13          ▸     amends the material cannabis cultivation facilities acquire from industrial hemp
14     cultivators and processors;
15          ▸     broadens the definition of a "research university" for purposes of academic medical
16     cannabis research;
17          ▸     amends a provision regarding disclosure of ownership interest for cannabis
18     production establishments and medical cannabis pharmacies;
19          ▸     amends provisions regarding licensing agencies giving consideration to existing
20     license holders when granting additional licenses in certain circumstances;
21          ▸     removes a provision limiting the size of signage for cannabis production
22     establishments and medical cannabis pharmacies;
23          ▸     amends agency reporting requirements to include information regarding testing of
24     cannabis and cannabis products;
25          ▸     allows a patient to renew a medical cannabis card for a longer period in certain

26     circumstances;
27          ▸     allows an individual physically present with a medical cannabis patient cardholder
28     in an emergency medical condition to handle medical cannabis to assist the patient
29     in the administration of the medical cannabis;
30          ▸     exempts a tetrahydrocannabinol from a felony provision related to vehicular
31     injuries; and
32          ▸     makes technical and conforming changes.
33     Money Appropriated in this Bill:
34          None
35     Other Special Clauses:
36          This bill provides a special effective date.
37          This bill provides a coordination clause.
38     Utah Code Sections Affected:
39     AMENDS:
40          4-41a-102, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
41          4-41a-201, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
42          4-41a-403, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
43          4-41a-802, as renumbered and amended by Laws of Utah 2018, Third Special Session,
44     Chapter 1
45          26-61a-102, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
46          26-61a-201, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
47          26-61a-301, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
48          26-61a-505, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
49          58-37-8, as last amended by Laws of Utah 2019, Chapter 58
50     Utah Code Sections Affected by Coordination Clause:
51          4-41a-102, as last amended by Laws of Utah 2019, First Special Session, Chapter 5
52     

53     Be it enacted by the Legislature of the state of Utah:
54          Section 1. Section 4-41a-102 is amended to read:
55          4-41a-102. Definitions.
56          As used in this chapter:

57          (1) "Active tetrahydrocannabinol" means delta-9-tetrahydrocannabinol and
58     tetrahydrocannabinolic acid.
59          [(1)] (2) "Cannabis" means the same as that term is defined in Section 26-61a-102.
60          [(2)] (3) "Cannabis cultivation facility" means a person that:
61          (a) possesses cannabis;
62          (b) (i) grows or intends to grow cannabis; and
63          (ii) acquires or intends to acquire industrial hemp or an industrial hemp product from
64     an industrial hemp cultivator, licensed under Title 4, Chapter 41, Hemp and Cannabinoid Act,
65     or an industrial hemp processor; and
66          (c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis
67     processing facility, or a medical cannabis research licensee.
68          [(3)] (4) "Cannabis cultivation facility agent" means an individual who:
69          (a) is an employee of a cannabis cultivation facility; and
70          (b) holds a valid cannabis production establishment agent registration card.
71          [(4)] (5) "Cannabis processing facility" means a person that:
72          (a) acquires or intends to acquire cannabis from a cannabis production establishment or
73     a holder of an industrial hemp processor license under Title 4, Chapter 41, Hemp and
74     Cannabinoid Act;
75          (b) possesses cannabis with the intent to manufacture a cannabis product;
76          (c) manufactures or intends to manufacture a cannabis product from unprocessed
77     cannabis or a cannabis extract; and
78          (d) sells or intends to sell a cannabis product to a medical cannabis pharmacy or a
79     medical cannabis research licensee.
80          [(5)] (6) "Cannabis processing facility agent" means an individual who:
81          (a) is an employee of a cannabis processing facility; and
82          (b) holds a valid cannabis production establishment agent registration card.
83          [(6)] (7) "Cannabis product" means the same as that term is defined in Section
84     26-61a-102.
85          [(7)] (8) "Cannabis production establishment" means a cannabis cultivation facility, a
86     cannabis processing facility, or an independent cannabis testing laboratory.
87          [(8)] (9) "Cannabis production establishment agent" means a cannabis cultivation

88     facility agent, a cannabis processing facility agent, or an independent cannabis testing
89     laboratory agent.
90          [(9)] (10) "Cannabis production establishment agent registration card" means a
91     registration card that the department issues that:
92          (a) authorizes an individual to act as a cannabis production establishment agent; and
93          (b) designates the type of cannabis production establishment for which an individual is
94     authorized to act as an agent.
95          [(10)] (11) "Community location" means a public or private school, a licensed
96     child-care facility or preschool, a church, a public library, a public playground, or a public park.
97          [(11)] (12) "Department" means the Department of Agriculture and Food.
98          [(12)] (13) "Family member" means a parent, step-parent, spouse, child, sibling,
99     step-sibling, uncle, aunt, nephew, niece, first cousin, mother-in-law, father-in-law,
100     brother-in-law, sister-in-law, son-in-law, daughter-in-law, grandparent, or grandchild.
101          [(13)] (14) "Independent cannabis testing laboratory" means a person that:
102          (a) conducts a chemical or other analysis of cannabis or a cannabis product; or
103          (b) acquires, possesses, and transports cannabis or a cannabis product with the intent to
104     conduct a chemical or other analysis of the cannabis or cannabis product.
105          [(14)] (15) "Independent cannabis testing laboratory agent" means an individual who:
106          (a) is an employee of an independent cannabis testing laboratory; and
107          (b) holds a valid cannabis production establishment agent registration card.
108          [(15)] (16) "Inventory control system" means a system described in Section 4-41a-103.
109          [(16)] (17) "Medical cannabis" means the same as that term is defined in Section
110     26-61a-102.
111          [(17)] (18) "Medical cannabis card" means the same as that term is defined in Section
112     26-61a-102.
113          [(18)] (19) "Medical cannabis pharmacy" means the same as that term is defined in
114     Section 26-61a-102.
115          [(19)] (20) "Medical cannabis pharmacy agent" means the same as that term is defined
116     in Section 26-61a-102.
117          [(20)] (21) "Medical cannabis research license" means a license that the department
118     issues to a research university for the purpose of obtaining and possessing medical cannabis for

119     academic research.
120          [(21)] (22) "Medical cannabis research licensee" means a research university that the
121     department licenses to obtain and possess medical cannabis for academic research, in
122     accordance with Section 4-41a-901.
123          [(22)] (23) "Medical cannabis treatment" means the same as that term is defined in
124     Section 26-61a-102.
125          [(23)] (24) "Medicinal dosage form" means the same as that term is defined in Section
126     26-61a-102.
127          [(24)] (25) "Qualified medical provider" means the same as that term is defined in
128     Section 26-61a-102.
129          [(25)] (26) "Qualified Production Enterprise Fund" means the fund created in Section
130     4-41a-104.
131          [(26)] (27) "Research university" means the same as that term is defined in Section
132     53B-7-702 and a private, nonprofit college or university in the state that:
133          (a) is accredited by the Northwest Commission on Colleges and Universities;
134          (b) grants doctoral degrees; and
135          (c) has a laboratory containing or a program researching a schedule I controlled
136     substance described in Section 58-37-4.
137          [(27)] (28) "State electronic verification system" means the system described in Section
138     26-61a-103.
139          [(28)] (29) "Tetrahydrocannabinol" means a substance derived from cannabis or a
140     synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).
141          [(29)] (30) "Total composite tetrahydrocannabinol" means
142     [delta-9-tetrahydrocannabinol and tetrahydrocannabinolic acid] all detectable forms of
143     tetrahydrocannabinol.
144          Section 2. Section 4-41a-201 is amended to read:
145          4-41a-201. Cannabis production establishment -- License.
146          (1) A person may not operate a cannabis production establishment without a license
147     that the department issues under this chapter.
148          (2) (a) (i) Subject to Subsections (6), (7), (8), and (13) and to Section 4-41a-205:
149          (A) for a licensing process that the department initiated before September 23, 2019, the

150     department shall use the procedures in Title 63G, Chapter 6a, Utah Procurement Code, to
151     review and rank applications for a cannabis production establishment license; and
152          (B) for a licensing process that the department initiates after September 23, 2019, the
153     department shall issue a license to operate a cannabis production establishment in accordance
154     with the procedures described in Subsection (2)(a)(iii).
155          (ii) The department may not issue a license to operate a cannabis production
156     establishment to an applicant who is not eligible for a license under this section.
157          (iii) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act,
158     the department shall make rules to specify a transparent and efficient process to:
159          (A) solicit applications for a license under this section;
160          (B) allow for comments and questions in the development of applications;
161          (C) timely and objectively evaluate applications;
162          (D) hold public hearings that the department deems appropriate; and
163          (E) select applicants to receive a license.
164          (b) An applicant is eligible for a license under this section if the applicant submits to
165     the department:
166          (i) subject to Subsection (2)(c), a proposed name and address, located in a zone
167     described in Subsection 4-41a-406(2)(a) or (b), where the applicant will operate the cannabis
168     production establishment;
169          (ii) the name and address of any individual who has:
170          (A) for a publicly traded company, a financial or voting interest of 2% or greater in the
171     proposed cannabis production establishment; [or]
172          (B) for a privately held company, a financial or voting interest in the proposed cannabis
173     production establishment; or
174          [(B)] (C) the power to direct or cause the management or control of a proposed
175     cannabis production establishment;
176          (iii) an operating plan that:
177          (A) complies with Section 4-41a-204;
178          (B) includes operating procedures that comply with this chapter and any law the
179     municipality or county in which the person is located adopts that is consistent with Section
180     4-41a-406; and

181          (C) the department approves;
182          (iv) a statement that the applicant will obtain and maintain a performance bond that a
183     surety authorized to transact surety business in the state issues in an amount of at least:
184          (A) $250,000 for each cannabis cultivation facility for which the applicant applies; or
185          (B) $50,000 for each cannabis processing facility or independent cannabis testing
186     laboratory for which the applicant applies;
187          (v) an application fee in an amount that, subject to Subsection 4-41a-104(5), the
188     department sets in accordance with Section 63J-1-504; and
189          (vi) a description of any investigation or adverse action taken by any licensing
190     jurisdiction, government agency, law enforcement agency, or court in any state for any
191     violation or detrimental conduct in relation to any of the applicant's cannabis-related operations
192     or businesses.
193          (c) (i) A person may not locate a cannabis production establishment:
194          (A) within 1,000 feet of a community location; or
195          (B) in or within 600 feet of a district that the relevant municipality or county has zoned
196     as primarily residential.
197          (ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured
198     from the nearest entrance to the cannabis production establishment by following the shortest
199     route of ordinary pedestrian travel to the property boundary of the community location or
200     residential area.
201          (iii) The department may grant a waiver to reduce the proximity requirements in
202     Subsection (2)(c)(i) by up to 20% if the department determines that it is not reasonably feasible
203     for the applicant to site the proposed cannabis production establishment without the waiver.
204          (iv) An applicant for a license under this section shall provide evidence of compliance
205     with the proximity requirements described in Subsection (2)(c)(i).
206          (3) If the department approves an application for a license under this section:
207          (a) the applicant shall pay the department an initial license fee in an amount that,
208     subject to Subsection 4-41a-104(5), the department sets in accordance with Section 63J-1-504;
209     and
210          (b) the department shall notify the Department of Public Safety of the license approval
211     and the names of each individual described in Subsection (2)(b)(ii).

212          (4) (a) Except as provided in Subsection (4)(b), the department shall require a separate
213     license for each type of cannabis production establishment and each location of a cannabis
214     production establishment.
215          (b) The department may issue a cannabis cultivation facility license and a cannabis
216     processing facility license to a person to operate at the same physical location or at separate
217     physical locations.
218          (5) If the department receives more than one application for a cannabis production
219     establishment within the same city or town, the department shall consult with the local land use
220     authority before approving any of the applications pertaining to that city or town.
221          (6) The department may not issue a license to operate an independent cannabis testing
222     laboratory to a person who:
223          (a) holds a license or has an ownership interest in a medical cannabis pharmacy, a
224     cannabis processing facility, or a cannabis cultivation facility;
225          (b) has an owner, officer, director, or employee whose family member holds a license
226     or has an ownership interest in a medical cannabis pharmacy, a cannabis processing facility, or
227     a cannabis cultivation facility; or
228          (c) proposes to operate the independent cannabis testing laboratory at the same physical
229     location as a medical cannabis pharmacy, a cannabis processing facility, or a cannabis
230     cultivation facility.
231          (7) The department may not issue a license to operate a cannabis production
232     establishment to an applicant if any individual described in Subsection (2)(b)(ii):
233          (a) has been convicted under state or federal law of:
234          (i) a felony; or
235          (ii) after December 3, 2018, a misdemeanor for drug distribution;
236          (b) is younger than 21 years old; or
237          (c) after September 23, 2019 until January 1, 2023, is actively serving as a legislator.
238          (8) (a) If an applicant for a cannabis production establishment license under this
239     section holds a license under Title 4, Chapter 41, Hemp and Cannabinoid Act, [or] the
240     department may not give preference to the applicant based on the applicant's status as a holder
241     of the license.
242          (b) If an applicant for a license to operate a cannabis cultivation facility under this

243     section holds a license to operate a medical cannabis pharmacy under Title 26, Chapter 61a,
244     Utah Medical Cannabis Act, the department:
245          [(a)] (i) shall consult with the Department of Health regarding the applicant [if the
246     license the applicant holds is a license under Title 26, Chapter 61a, Utah Medical Cannabis
247     Act]; and
248          [(b)] (ii) may [not] give [preference] consideration to the applicant based on the
249     applicant's status as a holder of a medical cannabis pharmacy license [described in this
250     Subsection (8).] if:
251          (A) the applicant demonstrates that a decrease in costs to patients is more likely to
252     result from the applicant's vertical integration than from a more competitive marketplace; and
253          (B) the department finds multiple other factors, in addition to the existing license, that
254     support granting the new license.
255          (9) The department may revoke a license under this part:
256          (a) if the cannabis production establishment does not begin cannabis production
257     operations within one year after the day on which the department issues the initial license;
258          (b) after the cannabis production establishment makes the same violation of this
259     chapter three times;
260          (c) if any individual described in Subsection (2)(b) is convicted, while the license is
261     active, under state or federal law of:
262          (i) a felony; or
263          (ii) after December 3, 2018, a misdemeanor for drug distribution; or
264          (d) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at
265     the time of application, or fails to supplement the information described in Subsection
266     (2)(b)(vi) with any investigation or adverse action that occurs after the submission of the
267     application.
268          (10) (a) A person who receives a cannabis production establishment license under this
269     chapter, if the municipality or county where the licensed cannabis production establishment
270     will be located requires a local land use permit, shall submit to the department a copy of the
271     licensee's approved application for the land use permit within 120 days after the day on which
272     the department issues the license.
273          (b) If a licensee fails to submit to the department a copy of the licensee's approved land

274     use permit application in accordance with Subsection (10)(a), the department may revoke the
275     licensee's license.
276          (11) The department shall deposit the proceeds of a fee that the department imposes
277     under this section into the Qualified Production Enterprise Fund.
278          (12) The department shall begin accepting applications under this part on or before
279     January 1, 2020.
280          (13) (a) The department's authority to issue a license under this section is plenary and is
281     not subject to review.
282          (b) Notwithstanding Subsection (2)(a)(i)(A), the decision of the department to award a
283     license to an applicant is not subject to:
284          (i) Title 63G, Chapter 6a, Part 16, Protests; or
285          (ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
286          Section 3. Section 4-41a-403 is amended to read:
287          4-41a-403. Advertising.
288          (1) Except as provided in Subsection (2), (3), or (4), a cannabis production
289     establishment may not advertise to the general public in any medium.
290          (2) A cannabis production establishment may advertise an employment opportunity at
291     the cannabis production establishment.
292          (3) A cannabis production establishment may maintain a website that:
293          (a) contains information about the establishment and employees; and
294          (b) does not advertise any medical cannabis, cannabis products, or medical cannabis
295     devices.
296          (4) Notwithstanding any municipal or county ordinance prohibiting signage, a cannabis
297     production establishment may use signage on the outside of the cannabis production
298     establishment that:
299          (a) includes only:
300          (i) the cannabis production establishment's name and hours of operation; and
301          (ii) a green cross; and
302          [(b) does not exceed four feet by five feet in size; and]
303          [(c)] (b) complies with local ordinances regulating signage.
304          Section 4. Section 4-41a-802 is amended to read:

305          4-41a-802. Report.
306          (1) At or before the November interim meeting each year, the department shall report to
307     the Health and Human Services Interim Committee on:
308          (a) the number of applications and renewal applications that the department receives
309     under this chapter;
310          (b) the number of each type of cannabis production facility that the department licenses
311     in each county;
312          (c) the amount of cannabis that licensees grow;
313          (d) the amount of cannabis that licensees manufacture into cannabis products;
314          (e) the number of licenses the department revokes under this chapter; [and]
315          (f) the department's operation of an independent cannabis testing laboratory under
316     Section 4-41a-201, including:
317          (i) the cannabis and cannabis products the department tested; and
318          (ii) the results of the tests the department performed; and
319          [(f)] (g) the expenses incurred and revenues generated under this chapter.
320          (2) The department may not include personally identifying information in the report
321     described in this section.
322          Section 5. Section 26-61a-102 is amended to read:
323          26-61a-102. Definitions.
324          As used in this chapter:
325          (1) "Blister" means a plastic cavity or pocket used to contain no more than a single
326     dose of cannabis or a cannabis product in a blister pack.
327          (2) "Blister pack" means a plastic, paper, or foil package with multiple blisters each
328     containing no more than a single dose of cannabis or a cannabis product.
329          (3) "Cannabis" means marijuana.
330          (4) "Cannabis cultivation facility" means the same as that term is defined in Section
331     4-41a-102.
332          (5) "Cannabis processing facility" means the same as that term is defined in Section
333     4-41a-102.
334          (6) "Cannabis product" means a product that:
335          (a) is intended for human use; and

336          (b) contains cannabis or tetrahydrocannabinol.
337          (7) "Cannabis production establishment" means the same as that term is defined in
338     Section 4-41a-102.
339          (8) "Cannabis production establishment agent" means the same as that term is defined
340     in Section 4-41a-102.
341          (9) "Cannabis production establishment agent registration card" means the same as that
342     term is defined in Section 4-41a-102.
343          (10) "Community location" means a public or private school, a licensed child-care
344     facility or preschool, a church, a public library, a public playground, or a public park.
345          (11) "Department" means the Department of Health.
346          (12) "Designated caregiver" means an individual:
347          (a) whom an individual with a medical cannabis patient card or a medical cannabis
348     guardian card designates as the patient's caregiver; and
349          (b) who registers with the department under Section 26-61a-202.
350          (13) "Dosing [parameters"] guidelines" means a quantity[, routes,] range and frequency
351     of administration for a recommended treatment of medical cannabis [in a medicinal dosage
352     form or a cannabis product in a medicinal dosage form].
353          (14) "Financial institution" means a bank, trust company, savings institution, or credit
354     union, chartered and supervised under state or federal law.
355          (15) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy
356     that the department authorizes, as part of the pharmacy's license, to deliver medical cannabis
357     shipments to a medical cannabis cardholder's home address to fulfill electronic orders that the
358     state central patient portal facilitates.
359          (16) "Independent cannabis testing laboratory" means the same as that term is defined
360     in Section 4-41a-102.
361          (17) "Inventory control system" means the system described in Section 4-41a-103.
362          (18) "Legal dosage limit" means an amount that:
363          (a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the
364     relevant qualified medical provider or the pharmacy medical provider, in accordance with
365     Subsection 26-61a-201(4) or (5), recommends; and
366          (b) may not exceed:

367          (i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and
368          (ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in total,
369     greater than 20 grams of active tetrahydrocannabinol.
370          [(18)] (19) "Marijuana" means the same as that term is defined in Section 58-37-2.
371          [(19)] (20) "Medical cannabis" means cannabis in a medicinal dosage form or a
372     cannabis product in a medicinal dosage form.
373          [(20)] (21) "Medical cannabis card" means a medical cannabis patient card, a medical
374     cannabis guardian card, or a medical cannabis caregiver card.
375          [(21)] (22) "Medical cannabis cardholder" means a holder of a medical cannabis card.
376          [(22)] (23) "Medical cannabis caregiver card" means an electronic document that a
377     cardholder may print or store on an electronic device or a physical card or document that:
378          (a) the department issues to an individual whom a medical cannabis patient cardholder
379     or a medical cannabis guardian cardholder designates as a designated caregiver; and
380          (b) is connected to the electronic verification system.
381          [(23)] (24) "Medical cannabis courier" means a courier that:
382          (a) the department licenses in accordance with Section 26-61a-604; and
383          (b) contracts with a home delivery medical cannabis pharmacy to deliver medical
384     cannabis shipments to fulfill electronic orders that the state central patient portal facilitates.
385          [(24)] (25) (a) "Medical cannabis device" means a device that an individual uses to
386     ingest or inhale cannabis in a medicinal dosage form or a cannabis product in a medicinal
387     dosage form.
388          (b) "Medical cannabis device" does not include a device that:
389          (i) facilitates cannabis combustion; or
390          (ii) an individual uses to ingest substances other than cannabis.
391          [(25)] (26) "Medical cannabis guardian card" means an electronic document that a
392     cardholder may print or store on an electronic device or a physical card or document that:
393          (a) the department issues to the parent or legal guardian of a minor with a qualifying
394     condition; and
395          (b) is connected to the electronic verification system.
396          [(26)] (27) "Medical cannabis patient card" means an electronic document that a
397     cardholder may print or store on an electronic device or a physical card or document that:

398          (a) the department issues to an individual with a qualifying condition; and
399          (b) is connected to the electronic verification system.
400          [(27)] (28) "Medical cannabis pharmacy" means a person that:
401          (a) (i) acquires or intends to acquire:
402          (A) cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage
403     form from a cannabis processing facility; or
404          (B) a medical cannabis device; or
405          (ii) possesses cannabis in a medicinal dosage form, a cannabis product in a medicinal
406     dosage form, or a medical cannabis device; and
407          (b) sells or intends to sell cannabis in a medicinal dosage form, a cannabis product in a
408     medicinal dosage form, or a medical cannabis device to a medical cannabis cardholder.
409          [(28)] (29) "Medical cannabis pharmacy agent" means an individual who:
410          (a) is an employee of a medical cannabis pharmacy; and
411          (b) who holds a valid medical cannabis pharmacy agent registration card.
412          [(29)] (30) "Medical cannabis pharmacy agent registration card" means a registration
413     card issued by the department that authorizes an individual to act as a medical cannabis
414     pharmacy agent.
415          [(30)] (31) "Medical cannabis shipment" means a shipment of medical cannabis or a
416     medical cannabis product that a home delivery medical cannabis pharmacy or a medical
417     cannabis courier delivers to a medical cannabis cardholder's home address to fulfill an
418     electronic medical cannabis order that the state central patient portal facilitates.
419          [(31)] (32) "Medical cannabis treatment" means cannabis in a medicinal dosage form, a
420     cannabis product in a medicinal dosage form, or a medical cannabis device.
421          [(32)] (33) (a) "Medicinal dosage form" means:
422          (i) for processed medical cannabis or a medical cannabis product, the following with a
423     specific and consistent cannabinoid content:
424          (A) a tablet;
425          (B) a capsule;
426          (C) a concentrated oil;
427          (D) a liquid suspension;
428          (E) a topical preparation;

429          (F) a transdermal preparation;
430          (G) a sublingual preparation;
431          (H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or
432     rectangular cuboid shape; or
433          (I) for use only after the individual's qualifying condition has failed to substantially
434     respond to at least two other forms described in this Subsection (32)(a)(i), a resin or wax;
435          (ii) for unprocessed cannabis flower, a blister pack, with each individual blister:
436          (A) containing a specific and consistent weight that does not exceed one gram and that
437     varies by no more than 10% from the stated weight; and
438          (B) after December 31, 2020, labeled with a barcode that provides information
439     connected to an inventory control system and the individual blister's content and weight; and
440          (iii) a form measured in grams, milligrams, or milliliters.
441          (b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:
442          (i) the medical cannabis cardholder has recently removed from the blister pack
443     described in Subsection (32)(a)(ii) for use; and
444          (ii) does not exceed the quantity described in Subsection (32)(a)(ii).
445          (c) "Medicinal dosage form" does not include:
446          (i) any unprocessed cannabis flower outside of the blister pack, except as provided in
447     Subsection (32)(b); or
448          (ii) a process of vaporizing and inhaling concentrated cannabis by placing the cannabis
449     on a nail or other metal object that is heated by a flame, including a blowtorch.
450          [(33)] (34) "Payment provider" means an entity that contracts with a cannabis
451     production establishment or medical cannabis pharmacy to facilitate transfers of funds between
452     the establishment or pharmacy and other businesses or individuals.
453          [(34)] (35) "Pharmacy medical provider" means the medical provider required to be on
454     site at a medical cannabis pharmacy under Section 26-61a-403.
455          [(35)] (36) "Provisional patient card" means a card that:
456          (a) the department issues to a minor with a qualifying condition for whom:
457          (i) a qualified medical provider has recommended a medical cannabis treatment; and
458          (ii) the department issues a medical cannabis guardian card to the minor's parent or
459     legal guardian; and

460          (b) is connected to the electronic verification system.
461          [(36)] (37) "Qualified medical provider" means an individual who is qualified to
462     recommend treatment with cannabis in a medicinal dosage form under Section 26-61a-106.
463          [(37)] (38) "Qualified Patient Enterprise Fund" means the enterprise fund created in
464     Section 26-61a-109.
465          [(38)] (39) "Qualifying condition" means a condition described in Section 26-61a-104.
466          [(39)] (40) "State central patient portal" means the website the department creates, in
467     accordance with Section 26-61a-601, to facilitate patient safety, education, and an electronic
468     medical cannabis order.
469          [(40)] (41) "State central patient portal medical provider" means a physician or
470     pharmacist that the department employs in relation to the state central patient portal to consult
471     with medical cannabis cardholders in accordance with Section 26-61a-602.
472          [(41)] (42) "State electronic verification system" means the system described in Section
473     26-61a-103.
474          [(42)] (43) "Valid form of photo identification" means a valid United States federal- or
475     state-issued photo identification, including:
476          (a) a driver license;
477          (b) a United States passport;
478          (c) a United States passport card; or
479          (d) a United States military identification card.
480          Section 6. Section 26-61a-201 is amended to read:
481          26-61a-201. Medical cannabis patient card -- Medical cannabis guardian card
482     application -- Fees -- Studies.
483          (1) On or before March 1, 2020, the department shall, within 15 days after the day on
484     which an individual who satisfies the eligibility criteria in this section or Section 26-61a-202
485     submits an application in accordance with this section or Section 26-61a-202:
486          (a) issue a medical cannabis patient card to an individual described in Subsection
487     (2)(a);
488          (b) issue a medical cannabis guardian card to an individual described in Subsection
489     (2)(b);
490          (c) issue a provisional patient card to a minor described in Subsection (2)(c); and

491          (d) issue a medical cannabis caregiver card to an individual described in Subsection
492     26-61a-202(4).
493          (2) (a) An individual is eligible for a medical cannabis patient card if:
494          (i) (A) the individual is at least 21 years old; or
495          (B) the individual is 18, 19, or 20 years old, the individual petitions the compassionate
496     use board under Section 26-61a-105, and the compassionate use board recommends department
497     approval of the petition;
498          (ii) the individual is a Utah resident;
499          (iii) the individual's qualified medical provider recommends treatment with medical
500     cannabis in accordance with Subsection (4);
501          (iv) the individual signs an acknowledgment stating that the individual received the
502     information described in Subsection (8); and
503          (v) the individual pays to the department a fee in an amount that, subject to Subsection
504     26-61a-109(5), the department sets in accordance with Section 63J-1-504.
505          (b) (i) An individual is eligible for a medical cannabis guardian card if the individual:
506          (A) is at least 18 years old;
507          (B) is a Utah resident;
508          (C) is the parent or legal guardian of a minor for whom the minor's qualified medical
509     provider recommends a medical cannabis treatment, the individual petitions the compassionate
510     use board under Section 26-61a-105, and the compassionate use board recommends department
511     approval of the petition;
512          (D) the individual signs an acknowledgment stating that the individual received the
513     information described in Subsection (8);
514          (E) pays to the department a fee in an amount that, subject to Subsection
515     26-61a-109(5), the department sets in accordance with Section 63J-1-504, plus the cost of the
516     criminal background check described in Section 26-61a-203; and
517          (F) the individual has not been convicted of a misdemeanor or felony drug distribution
518     offense under either state or federal law, unless the individual completed any imposed sentence
519     six months or more before the day on which the individual applies for a medical cannabis
520     guardian card.
521          (ii) The department shall notify the Department of Public Safety of each individual that

522     the department registers for a medical cannabis guardian card.
523          (c) (i) A minor is eligible for a provisional patient card if:
524          (A) the minor has a qualifying condition;
525          (B) the minor's qualified medical provider recommends a medical cannabis treatment
526     to address the minor's qualifying condition;
527          (C) the minor's parent or legal guardian petitions the compassionate use board under
528     Section 26-61a-105, and the compassionate use board recommends department approval of the
529     petition; and
530          (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian card
531     under Subsection (2)(b).
532          (ii) The department shall automatically issue a provisional patient card to the minor
533     described in Subsection (2)(c)(i) at the same time the department issues a medical cannabis
534     guardian card to the minor's parent or legal guardian.
535          (3) (a) An individual who is eligible for a medical cannabis card described in
536     Subsection (2)(a) or (b) shall submit an application for a medical cannabis card to the
537     department:
538          (i) through an electronic application connected to the state electronic verification
539     system;
540          (ii) with the recommending qualified medical provider while in the recommending
541     qualified medical provider's office; and
542          (iii) with information including:
543          (A) the applicant's name, gender, age, and address;
544          (B) the number of the applicant's valid form of photo identification;
545          (C) for a medical cannabis guardian card, the name, gender, and age of the minor
546     receiving a medical cannabis treatment under the cardholder's medical cannabis guardian card;
547     and
548          (D) for a provisional patient card, the name of the minor's parent or legal guardian who
549     holds the associated medical cannabis guardian card.
550          (b) The department shall ensure that a medical cannabis card the department issues
551     under this section contains the information described in Subsection (3)(a)(iii).
552          (c) (i) If a qualified medical provider determines that, because of age, illness, or

553     disability, a medical cannabis patient cardholder requires assistance in administering the
554     medical cannabis treatment that the qualified medical provider recommends, the qualified
555     medical provider may indicate the cardholder's need in the state electronic verification system.
556          (ii) If a qualified medical provider makes the indication described in Subsection
557     (3)(c)(i):
558          (A) the department shall add a label to the relevant medical cannabis patient card
559     indicating the cardholder's need for assistance; and
560          (B) any adult who is 21 years old or older and who is physically present with the
561     cardholder at the time the cardholder needs to use the recommended medical cannabis
562     treatment may handle the medical cannabis treatment and any associated medical cannabis
563     device as needed to assist the cardholder in administering the recommended medical cannabis
564     treatment[, including in the event of an emergency medical condition under Subsection
565     26-61a-204(2).]; and
566          (C) an individual of any age who is physically present with the cardholder in the event
567     of an emergency medical condition, as that term is defined in Section 31A-22-627, may handle
568     the medical cannabis treatment and any associated medical cannabis device as needed to assist
569     the cardholder in administering the recommended medical cannabis treatment.
570          (iii) A non-cardholding individual acting under Subsection (3)(c)(ii)(B) or (C) may not:
571          (A) ingest or inhale medical cannabis;
572          (B) possess, transport, or handle medical cannabis or a medical cannabis device outside
573     of the immediate area where the cardholder is present or with an intent other than to provide
574     assistance to the cardholder; or
575          (C) possess, transport, or handle medical cannabis or a medical cannabis device when
576     the cardholder is not in the process of being dosed with medical cannabis.
577          (4) To recommend a medical cannabis treatment to a patient or to renew a
578     recommendation, a qualified medical provider shall:
579          (a) before recommending cannabis in a medicinal dosage form or a cannabis product in
580     a medicinal dosage form:
581          (i) verify the patient's and, for a minor patient, the minor patient's parent or legal
582     guardian's valid form of identification described in Subsection (3)(a);
583          (ii) review any record related to the patient and, for a minor patient, the patient's parent

584     or legal guardian in:
585          (A) the state electronic verification system; and
586          (B) the controlled substance database created in Section 58-37f-201; and
587          (iii) consider the recommendation in light of the patient's qualifying condition and
588     history of medical cannabis and controlled substance use; and
589          (b) state in the qualified medical provider's recommendation that the patient:
590          (i) suffers from a qualifying condition, including the type of qualifying condition; and
591          (ii) may benefit from treatment with cannabis in a medicinal dosage form or a cannabis
592     product in a medicinal dosage form.
593          (5) (a) Except as provided in Subsection (5)(b), a medical cannabis card that the
594     department issues under this section is valid for the lesser of:
595          (i) an amount of time that the qualified medical provider determines; or
596          (ii) (A) for the first issuance, 30 days; [or]
597          (B) except as provided in Subsection (5)(a)(ii)(C), for a renewal, six months[.]; or
598          (C) for a renewal, one year if, after at least one year following the issuance of the
599     original medical cannabis card, the qualified medical provider determines that the patient has
600     been stabilized on the medical cannabis treatment and a one-year renewal period is justified.
601          (b) (i) A medical cannabis card that the department issues in relation to a terminal
602     illness described in Section 26-61a-104 does not expire.
603          (ii) The recommending qualified medical provider may revoke a recommendation that
604     the provider made in relation to a terminal illness described in Section 26-61a-104 if the
605     medical cannabis cardholder no longer has the terminal illness.
606          (6) (a) A medical cannabis patient card or a medical cannabis guardian card is
607     renewable if:
608          (i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a) or
609     (b); or
610          (ii) the cardholder received the medical cannabis card through the recommendation of
611     the compassionate use board under Section 26-61a-105.
612          (b) A cardholder described in Subsection (6)(a) may renew the cardholder's card:
613          (i) using the application process described in Subsection (3); or
614          (ii) through phone or video conference with the qualified medical provider who made

615     the recommendation underlying the card, at the qualifying medical provider's discretion.
616          (c) A cardholder under Subsection (2)(a) or (b) who renews the cardholder's card shall
617     pay to the department a renewal fee in an amount that:
618          (i) subject to Subsection 26-61a-109(5), the department sets in accordance with Section
619     63J-1-504; and
620          (ii) may not exceed the cost of the relatively lower administrative burden of renewal in
621     comparison to the original application process.
622          (d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional
623     patient card renews automatically at the time the minor's parent or legal guardian renews the
624     parent or legal guardian's associated medical cannabis guardian card.
625          (e) The department may revoke a medical cannabis guardian card if the cardholder
626     under Subsection (2)(b) is convicted of a misdemeanor or felony drug distribution offense
627     under either state or federal law.
628          (7) (a) A cardholder under this section shall carry the cardholder's valid medical
629     cannabis card with the patient's name.
630          (b) (i) A medical cannabis patient cardholder or a provisional patient cardholder may
631     purchase, in accordance with this chapter and the recommendation underlying the card,
632     cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a
633     medical cannabis device.
634          (ii) A cardholder under this section may possess or transport, in accordance with this
635     chapter and the recommendation underlying the card, cannabis in a medicinal dosage form, a
636     cannabis product in a medicinal dosage form, or a medical cannabis device.
637          (iii) To address the qualifying condition underlying the medical cannabis treatment
638     recommendation:
639          (A) a medical cannabis patient cardholder or a provisional patient cardholder may use
640     cannabis in a medicinal dosage form, a medical cannabis product in a medicinal dosage form,
641     or a medical cannabis device; and
642          (B) a medical cannabis guardian cardholder may assist the associated provisional
643     patient cardholder with the use of cannabis in a medicinal dosage form, a medical cannabis
644     product in a medicinal dosage form, or a medical cannabis device.
645          (c) If a licensed medical cannabis pharmacy is not operating within the state after

646     January 1, 2021, a cardholder under this section is not subject to prosecution for the possession
647     of:
648          (i) no more than 113 grams of marijuana in a medicinal dosage form;
649          (ii) an amount of cannabis product in a medicinal dosage form that contains no more
650     than 20 grams of tetrahydrocannabinol; or
651          (iii) marijuana drug paraphernalia.
652          (8) The department shall establish by rule, in accordance with Title 63G, Chapter 3,
653     Utah Administrative Rulemaking Act, a process to provide information regarding the following
654     to an individual receiving a medical cannabis card:
655          (a) risks associated with medical cannabis treatment;
656          (b) the fact that a condition's listing as a qualifying condition does not suggest that
657     medical cannabis treatment is an effective treatment or cure for that condition, as described in
658     Subsection 26-61a-104(1); and
659          (c) other relevant warnings and safety information that the department determines.
660          (9) The department may establish procedures by rule, in accordance with Title 63G,
661     Chapter 3, Utah Administrative Rulemaking Act, to implement the application and issuance
662     provisions of this section.
663          (10) (a) A person may submit to the department a request to conduct a research study
664     using medical cannabis cardholder data that the state electronic verification system contains.
665          (b) The department shall review a request described in Subsection (10)(a) to determine
666     whether an institutional review board, as that term is defined in Section 26-61-102, could
667     approve the research study.
668          (c) At the time an individual applies for a medical cannabis card, the department shall
669     notify the individual:
670          (i) of how the individual's information will be used as a cardholder;
671          (ii) that by applying for a medical cannabis card, unless the individual withdraws
672     consent under Subsection (10)(d), the individual consents to the use of the individual's
673     information for external research; and
674          (iii) that the individual may withdraw consent for the use of the individual's
675     information for external research at any time, including at the time of application.
676          (d) An applicant may, through the medical cannabis card application, and a medical

677     cannabis cardholder may, through the state central patient portal, withdraw the applicant's or
678     cardholder's consent to participate in external research at any time.
679          (e) The department may release, for the purposes of a study described in this
680     Subsection (10), information about a cardholder under this section who consents to participate
681     under Subsection (10)(c).
682          (f) If an individual withdraws consent under Subsection (10)(d), the withdrawal of
683     consent:
684          (i) applies to external research that is initiated after the withdrawal of consent; and
685          (ii) does not apply to research that was initiated before the withdrawal of consent.
686          (g) The department may establish standards for a medical research study's validity, by
687     rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
688          Section 7. Section 26-61a-301 is amended to read:
689          26-61a-301. Medical cannabis pharmacy -- License -- Eligibility.
690          (1) A person may not operate as a medical cannabis pharmacy without a license that
691     the department issues under this part.
692          (2) (a) (i) Subject to Subsections (4) and (5) and to Section 26-61a-305, the department
693     shall issue a license to operate a medical cannabis pharmacy in accordance with Title 63G,
694     Chapter 6a, Utah Procurement Code.
695          (ii) The department may not issue a license to operate a medical cannabis pharmacy to
696     an applicant who is not eligible for a license under this section.
697          (b) An applicant is eligible for a license under this section if the applicant submits to
698     the department:
699          (i) subject to Subsection (2)(c), a proposed name and address where the applicant will
700     operate the medical cannabis pharmacy;
701          (ii) the name and address of an individual who:
702          (A) for a publicly traded company, has a financial or voting interest of 2% or greater in
703     the proposed medical cannabis pharmacy; [or]
704          (B) for a privately held company, a financial or voting interest in the proposed medical
705     cannabis pharmacy; or
706          (C) has the power to direct or cause the management or control of a proposed medical
707     cannabis [production establishment] pharmacy;

708          (iii) a statement that the applicant will obtain and maintain a performance bond that a
709     surety authorized to transact surety business in the state issues in an amount of at least
710     $125,000 for each application that the applicant submits to the department;
711          (iv) an operating plan that:
712          (A) complies with Section 26-61a-304;
713          (B) includes operating procedures to comply with the operating requirements for a
714     medical cannabis pharmacy described in this chapter and with a relevant municipal or county
715     law that is consistent with Section 26-61a-507; and
716          (C) the department approves;
717          (v) an application fee in an amount that, subject to Subsection 26-61a-109(5), the
718     department sets in accordance with Section 63J-1-504; and
719          (vi) a description of any investigation or adverse action taken by any licensing
720     jurisdiction, government agency, law enforcement agency, or court in any state for any
721     violation or detrimental conduct in relation to any of the applicant's cannabis-related operations
722     or businesses.
723          (c) (i) A person may not locate a medical cannabis pharmacy:
724          (A) within 200 feet of a community location; or
725          (B) in or within 600 feet of a district that the relevant municipality or county has zoned
726     as primarily residential.
727          (ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured
728     from the nearest entrance to the medical cannabis pharmacy establishment by following the
729     shortest route of ordinary pedestrian travel to the property boundary of the community location
730     or residential area.
731          (iii) The department may grant a waiver to reduce the proximity requirements in
732     Subsection (2)(c)(i) by up to 20% if the department determines that it is not reasonably feasible
733     for the applicant to site the proposed medical cannabis pharmacy without the waiver.
734          (iv) An applicant for a license under this section shall provide evidence of compliance
735     with the proximity requirements described in Subsection (2)(c)(i).
736          (d) The department may not issue a license to an eligible applicant that the department
737     has selected to receive a license until the selected eligible applicant obtains the performance
738     bond described in Subsection (2)(b)(iii).

739          (e) If the department receives more than one application for a medical cannabis
740     pharmacy within the same city or town, the department shall consult with the local land use
741     authority before approving any of the applications pertaining to that city or town.
742          (3) If the department selects an applicant for a medical cannabis pharmacy license
743     under this section, the department shall:
744          (a) charge the applicant an initial license fee in an amount that, subject to Subsection
745     26-61a-109(5), the department sets in accordance with Section 63J-1-504; and
746          (b) notify the Department of Public Safety of the license approval and the names of
747     each individual described in Subsection (2)(b)(ii).
748          (4) The department may not issue a license to operate a medical cannabis pharmacy to
749     an applicant if an individual described in Subsection (2)(b)(ii):
750          (a) has been convicted under state or federal law of:
751          (i) a felony; or
752          (ii) after December 3, 2018, a misdemeanor for drug distribution;
753          (b) is younger than 21 years old; or
754          (c) after the effective date of this bill until January 1, 2023, is actively serving as a
755     legislator.
756          (5) (a) If an applicant for a medical cannabis pharmacy license under this section holds
757     a license under Title 4, Chapter 41, Hemp and Cannabinoid Act, [or] the department may not
758     give preference to the applicant based on the applicant's status as a holder of the license.
759          (b) If an applicant for a medical cannabis pharmacy license under this section holds a
760     license to operate a cannabis cultivation facility under Title 4, Chapter 41a, Cannabis
761     Production Establishments, the department:
762          [(a)] (i) shall consult with the Department of Agriculture and Food regarding the
763     applicant; and
764          [(b)] (ii) may [not] give [preference] consideration to the applicant based on the
765     applicant's status as a holder of a license [described in this Subsection (5).] to operate a
766     cannabis cultivation facility if:
767          (A) the applicant demonstrates that a decrease in costs to patients is more likely to
768     result from the applicant's vertical integration than from a more competitive marketplace; and
769          (B) the department finds multiple other factors, in addition to the existing license, that

770     support granting the new license.
771          (6) The department may revoke a license under this part if:
772          (a) the medical cannabis pharmacy does not begin operations within one year after the
773     day on which the department issues the initial license;
774          (b) the medical cannabis pharmacy makes the same violation of this chapter three
775     times;
776          (c) an individual described in Subsection (2)(b)(ii) is convicted, while the license is
777     active, under state or federal law of:
778          (i) a felony; or
779          (ii) after December 3, 2018, a misdemeanor for drug distribution; or
780          (d) the licensee fails to provide the information described in Subsection (2)(b)(vi) at
781     the time of application, or fails to supplement the information described in Subsection
782     (2)(b)(vi) with any investigation or adverse action that occurs after the submission of the
783     application.
784          (7) (a) A person who receives a medical cannabis pharmacy license under this chapter,
785     if the municipality or county where the licensed medical cannabis pharmacy will be located
786     requires a local land use permit, shall submit to the department a copy of the licensee's
787     approved application for the land use permit within 120 days after the day on which the
788     department issues the license.
789          (b) If a licensee fails to submit to the department a copy the licensee's approved land
790     use permit application in accordance with Subsection (7)(a), the department may revoke the
791     licensee's license.
792          (8) The department shall deposit the proceeds of a fee imposed by this section in the
793     Qualified Patient Enterprise Fund.
794          (9) The department shall begin accepting applications under this part on or before
795     March 1, 2020.
796          (10) (a) The department's authority to issue a license under this section is plenary and is
797     not subject to review.
798          (b) Notwithstanding Subsection (2), the decision of the department to award a license
799     to an applicant is not subject to:
800          (i) Title 63G, Chapter 6a, Part 16, Protests; or

801          (ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.
802          Section 8. Section 26-61a-505 is amended to read:
803          26-61a-505. Advertising.
804          (1) Except as provided in Subsections (2) and (3), a medical cannabis pharmacy may
805     not advertise in any medium.
806          (2) Notwithstanding any municipal or county ordinance prohibiting signage, a medical
807     cannabis pharmacy may use signage on the outside of the medical cannabis pharmacy that:
808          (a) includes only:
809          (i) the medical cannabis pharmacy's name and hours of operation; and
810          (ii) a green cross; and
811          [(b) does not exceed four feet by five feet in size; and]
812          [(c)] (b) complies with local ordinances regulating signage.
813          (3) A medical cannabis pharmacy may maintain a website that includes information
814     about:
815          (a) the location and hours of operation of the medical cannabis pharmacy;
816          (b) a product or service available at the medical cannabis pharmacy;
817          (c) personnel affiliated with the medical cannabis pharmacy;
818          (d) best practices that the medical cannabis pharmacy upholds; and
819          (e) educational material related to the medical use of cannabis.
820          Section 9. Section 58-37-8 is amended to read:
821          58-37-8. Prohibited acts -- Penalties.
822          (1) Prohibited acts A -- Penalties and reporting:
823          (a) Except as authorized by this chapter, it is unlawful for a person to knowingly and
824     intentionally:
825          (i) produce, manufacture, or dispense, or to possess with intent to produce,
826     manufacture, or dispense, a controlled or counterfeit substance;
827          (ii) distribute a controlled or counterfeit substance, or to agree, consent, offer, or
828     arrange to distribute a controlled or counterfeit substance;
829          (iii) possess a controlled or counterfeit substance with intent to distribute; or
830          (iv) engage in a continuing criminal enterprise where:
831          (A) the person participates, directs, or engages in conduct that results in a violation of

832     Chapters 37, Utah Controlled Substances Act, 37a, Utah Drug Paraphernalia Act, 37b,
833     Imitation Controlled Substances Act, 37c, Utah Controlled Substance Precursor Act, or 37d,
834     Clandestine Drug Lab Act, that is a felony; and
835          (B) the violation is a part of a continuing series of two or more violations of Chapters
836     37, Utah Controlled Substances Act, 37a, Utah Drug Paraphernalia Act, 37b, Imitation
837     Controlled Substances Act, 37c, Utah Controlled Substance Precursor Act, or 37d, Clandestine
838     Drug Lab Act, on separate occasions that are undertaken in concert with five or more persons
839     with respect to whom the person occupies a position of organizer, supervisor, or any other
840     position of management.
841          (b) A person convicted of violating Subsection (1)(a) with respect to:
842          (i) a substance or a counterfeit of a substance classified in Schedule I or II, a controlled
843     substance analog, or gammahydroxybutyric acid as listed in Schedule III is guilty of a second
844     degree felony, punishable by imprisonment for not more than 15 years, and upon a second or
845     subsequent conviction is guilty of a first degree felony;
846          (ii) a substance or a counterfeit of a substance classified in Schedule III or IV, or
847     marijuana, or a substance listed in Section 58-37-4.2 is guilty of a third degree felony, and
848     upon a second or subsequent conviction is guilty of a second degree felony; or
849          (iii) a substance or a counterfeit of a substance classified in Schedule V is guilty of a
850     class A misdemeanor and upon a second or subsequent conviction is guilty of a third degree
851     felony.
852          (c) A person who has been convicted of a violation of Subsection (1)(a)(ii) or (iii) may
853     be sentenced to imprisonment for an indeterminate term as provided by law, but if the trier of
854     fact finds a firearm as defined in Section 76-10-501 was used, carried, or possessed on the
855     person or in the person's immediate possession during the commission or in furtherance of the
856     offense, the court shall additionally sentence the person convicted for a term of one year to run
857     consecutively and not concurrently; and the court may additionally sentence the person
858     convicted for an indeterminate term not to exceed five years to run consecutively and not
859     concurrently.
860          (d) A person convicted of violating Subsection (1)(a)(iv) is guilty of a first degree
861     felony punishable by imprisonment for an indeterminate term of not less than seven years and
862     which may be for life. Imposition or execution of the sentence may not be suspended, and the

863     person is not eligible for probation.
864          (e) The Administrative Office of the Courts shall report to the Division of
865     Occupational and Professional Licensing the name, case number, date of conviction, and if
866     known, the date of birth of each person convicted of violating Subsection (1)(a).
867          (2) Prohibited acts B -- Penalties and reporting:
868          (a) It is unlawful:
869          (i) for a person knowingly and intentionally to possess or use a controlled substance
870     analog or a controlled substance, unless it was obtained under a valid prescription or order,
871     directly from a practitioner while acting in the course of the person's professional practice, or as
872     otherwise authorized by this chapter;
873          (ii) for an owner, tenant, licensee, or person in control of a building, room, tenement,
874     vehicle, boat, aircraft, or other place knowingly and intentionally to permit them to be occupied
875     by persons unlawfully possessing, using, or distributing controlled substances in any of those
876     locations; or
877          (iii) for a person knowingly and intentionally to possess an altered or forged
878     prescription or written order for a controlled substance.
879          (b) A person convicted of violating Subsection (2)(a)(i) with respect to:
880          (i) marijuana, if the amount is 100 pounds or more, is guilty of a second degree felony;
881     or
882          (ii) a substance classified in Schedule I or II, or a controlled substance analog, is guilty
883     of a class A misdemeanor on a first or second conviction, and on a third or subsequent
884     conviction is guilty of a third degree felony.
885          (c) Upon a person's conviction of a violation of this Subsection (2) subsequent to a
886     conviction under Subsection (1)(a), that person shall be sentenced to a one degree greater
887     penalty than provided in this Subsection (2).
888          (d) A person who violates Subsection (2)(a)(i) with respect to all other controlled
889     substances not included in Subsection (2)(b)(i) or (ii), including a substance listed in Section
890     58-37-4.2, or marijuana, is guilty of a class B misdemeanor. Upon a third conviction the
891     person is guilty of a class A misdemeanor, and upon a fourth or subsequent conviction the
892     person is guilty of a third degree felony.
893          (e) A person convicted of violating Subsection (2)(a)(i) while inside the exterior

894     boundaries of property occupied by a correctional facility as defined in Section 64-13-1 or a
895     public jail or other place of confinement shall be sentenced to a penalty one degree greater than
896     provided in Subsection (2)(b), and if the conviction is with respect to controlled substances as
897     listed in:
898          (i) Subsection (2)(b), the person may be sentenced to imprisonment for an
899     indeterminate term as provided by law, and:
900          (A) the court shall additionally sentence the person convicted to a term of one year to
901     run consecutively and not concurrently; and
902          (B) the court may additionally sentence the person convicted for an indeterminate term
903     not to exceed five years to run consecutively and not concurrently; and
904          (ii) Subsection (2)(d), the person may be sentenced to imprisonment for an
905     indeterminate term as provided by law, and the court shall additionally sentence the person
906     convicted to a term of six months to run consecutively and not concurrently.
907          (f) A person convicted of violating Subsection (2)(a)(ii) or (iii) is:
908          (i) on a first conviction, guilty of a class B misdemeanor;
909          (ii) on a second conviction, guilty of a class A misdemeanor; and
910          (iii) on a third or subsequent conviction, guilty of a third degree felony.
911          (g) A person is subject to the penalties under Subsection (2)(h) who, in an offense not
912     amounting to a violation of Section 76-5-207:
913          (i) violates Subsection (2)(a)(i) by knowingly and intentionally having in the person's
914     body any measurable amount of a controlled substance, except for
915     11-nor-9-carboxy-tetrahyrdocannabinol; and
916          (ii) operates a motor vehicle as defined in Section 76-5-207 in a negligent manner,
917     causing serious bodily injury as defined in Section 76-1-601 or the death of another.
918          (h) A person who violates Subsection (2)(g) by having in the person's body:
919          (i) a controlled substance classified under Schedule I, other than those described in
920     Subsection (2)(h)(ii), or a controlled substance classified under Schedule II is guilty of a second
921     degree felony;
922          (ii) marijuana, tetrahydrocannabinols, or equivalents described in Subsection
923     58-37-4(2)(a)(iii)(S) or (AA), or a substance listed in Section 58-37-4.2 is guilty of a third
924     degree felony; or

925          (iii) a controlled substance classified under Schedules III, IV, or V is guilty of a class A
926     misdemeanor.
927          (i) A person is guilty of a separate offense for each victim suffering serious bodily
928     injury or death as a result of the person's negligent driving in violation of Subsection(2)(g)
929     whether or not the injuries arise from the same episode of driving.
930          (j) The Administrative Office of the Courts shall report to the Division of Occupational
931     and Professional Licensing the name, case number, date of conviction, and if known, the date
932     of birth of each person convicted of violating Subsection (2)(a).
933          (3) Prohibited acts C -- Penalties:
934          (a) It is unlawful for a person knowingly and intentionally:
935          (i) to use in the course of the manufacture or distribution of a controlled substance a
936     license number which is fictitious, revoked, suspended, or issued to another person or, for the
937     purpose of obtaining a controlled substance, to assume the title of, or represent oneself to be, a
938     manufacturer, wholesaler, apothecary, physician, dentist, veterinarian, or other authorized
939     person;
940          (ii) to acquire or obtain possession of, to procure or attempt to procure the
941     administration of, to obtain a prescription for, to prescribe or dispense to a person known to be
942     attempting to acquire or obtain possession of, or to procure the administration of a controlled
943     substance by misrepresentation or failure by the person to disclose receiving a controlled
944     substance from another source, fraud, forgery, deception, subterfuge, alteration of a
945     prescription or written order for a controlled substance, or the use of a false name or address;
946          (iii) to make a false or forged prescription or written order for a controlled substance,
947     or to utter the same, or to alter a prescription or written order issued or written under the terms
948     of this chapter; or
949          (iv) to make, distribute, or possess a punch, die, plate, stone, or other thing designed to
950     print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or
951     device of another or any likeness of any of the foregoing upon any drug or container or labeling
952     so as to render a drug a counterfeit controlled substance.
953          (b) (i) A first or second conviction under Subsection (3)(a)(i), (ii), or (iii) is a class A
954     misdemeanor.
955          (ii) A third or subsequent conviction under Subsection (3)(a)(i), (ii), or (iii) is a third

956     degree felony.
957          (c) A violation of Subsection (3)(a)(iv) is a third degree felony.
958          (4) Prohibited acts D -- Penalties:
959          (a) Notwithstanding other provisions of this section, a person not authorized under this
960     chapter who commits any act that is unlawful under Subsection (1)(a) or Section 58-37b-4 is
961     upon conviction subject to the penalties and classifications under this Subsection (4) if the trier
962     of fact finds the act is committed:
963          (i) in a public or private elementary or secondary school or on the grounds of any of
964     those schools during the hours of 6 a.m. through 10 p.m.;
965          (ii) in a public or private vocational school or postsecondary institution or on the
966     grounds of any of those schools or institutions during the hours of 6 a.m. through 10 p.m.;
967          (iii) in or on the grounds of a preschool or child-care facility during the preschool's or
968     facility's hours of operation;
969          (iv) in a public park, amusement park, arcade, or recreation center when the public or
970     amusement park, arcade, or recreation center is open to the public;
971          (v) in or on the grounds of a house of worship as defined in Section 76-10-501;
972          (vi) in or on the grounds of a library when the library is open to the public;
973          (vii) within an area that is within 100 feet of any structure, facility, or grounds included
974     in Subsections (4)(a)(i), (ii), (iii), (iv), (v), and (vi);
975          (viii) in the presence of a person younger than 18 years of age, regardless of where the
976     act occurs; or
977          (ix) for the purpose of facilitating, arranging, or causing the transport, delivery, or
978     distribution of a substance in violation of this section to an inmate or on the grounds of a
979     correctional facility as defined in Section 76-8-311.3.
980          (b) (i) A person convicted under this Subsection (4) is guilty of a first degree felony
981     and shall be imprisoned for a term of not less than five years if the penalty that would
982     otherwise have been established but for this Subsection (4) would have been a first degree
983     felony.
984          (ii) Imposition or execution of the sentence may not be suspended, and the person is
985     not eligible for probation.
986          (c) If the classification that would otherwise have been established would have been

987     less than a first degree felony but for this Subsection (4), a person convicted under this
988     Subsection (4) is guilty of one degree more than the maximum penalty prescribed for that
989     offense. This Subsection (4)(c) does not apply to a violation of Subsection (2)(g).
990          (d) (i) If the violation is of Subsection (4)(a)(ix):
991          (A) the person may be sentenced to imprisonment for an indeterminate term as
992     provided by law, and the court shall additionally sentence the person convicted for a term of
993     one year to run consecutively and not concurrently; and
994          (B) the court may additionally sentence the person convicted for an indeterminate term
995     not to exceed five years to run consecutively and not concurrently; and
996          (ii) the penalties under this Subsection (4)(d) apply also to a person who, acting with
997     the mental state required for the commission of an offense, directly or indirectly solicits,
998     requests, commands, coerces, encourages, or intentionally aids another person to commit a
999     violation of Subsection (4)(a)(ix).
1000          (e) It is not a defense to a prosecution under this Subsection (4) that:
1001          (i) the actor mistakenly believed the individual to be 18 years of age or older at the
1002     time of the offense or was unaware of the individual's true age; or
1003          (ii) the actor mistakenly believed that the location where the act occurred was not as
1004     described in Subsection (4)(a) or was unaware that the location where the act occurred was as
1005     described in Subsection (4)(a).
1006          (5) A violation of this chapter for which no penalty is specified is a class B
1007     misdemeanor.
1008          (6) (a) For purposes of penalty enhancement under Subsections (1) and (2), a plea of
1009     guilty or no contest to a violation or attempted violation of this section or a plea which is held
1010     in abeyance under Title 77, Chapter 2a, Pleas in Abeyance, is the equivalent of a conviction,
1011     even if the charge has been subsequently reduced or dismissed in accordance with the plea in
1012     abeyance agreement.
1013          (b) A prior conviction used for a penalty enhancement under Subsection (2) shall be a
1014     conviction that is:
1015          (i) from a separate criminal episode than the current charge; and
1016          (ii) from a conviction that is separate from any other conviction used to enhance the
1017     current charge.

1018          (7) A person may be charged and sentenced for a violation of this section,
1019     notwithstanding a charge and sentence for a violation of any other section of this chapter.
1020          (8) (a) A penalty imposed for violation of this section is in addition to, and not in lieu
1021     of, a civil or administrative penalty or sanction authorized by law.
1022          (b) When a violation of this chapter violates a federal law or the law of another state,
1023     conviction or acquittal under federal law or the law of another state for the same act is a bar to
1024     prosecution in this state.
1025          (9) In any prosecution for a violation of this chapter, evidence or proof that shows a
1026     person or persons produced, manufactured, possessed, distributed, or dispensed a controlled
1027     substance or substances, is prima facie evidence that the person or persons did so with
1028     knowledge of the character of the substance or substances.
1029          (10) This section does not prohibit a veterinarian, in good faith and in the course of the
1030     veterinarian's professional practice only and not for humans, from prescribing, dispensing, or
1031     administering controlled substances or from causing the substances to be administered by an
1032     assistant or orderly under the veterinarian's direction and supervision.
1033          (11) Civil or criminal liability may not be imposed under this section on:
1034          (a) a person registered under this chapter who manufactures, distributes, or possesses
1035     an imitation controlled substance for use as a placebo or investigational new drug by a
1036     registered practitioner in the ordinary course of professional practice or research; or
1037          (b) a law enforcement officer acting in the course and legitimate scope of the officer's
1038     employment.
1039          (12) (a) Civil or criminal liability may not be imposed under this section on any Indian,
1040     as defined in Section 58-37-2, who uses, possesses, or transports peyote for bona fide
1041     traditional ceremonial purposes in connection with the practice of a traditional Indian religion
1042     as defined in Section 58-37-2.
1043          (b) In a prosecution alleging violation of this section regarding peyote as defined in
1044     Section 58-37-4, it is an affirmative defense that the peyote was used, possessed, or transported
1045     by an Indian for bona fide traditional ceremonial purposes in connection with the practice of a
1046     traditional Indian religion.
1047          (c) (i) The defendant shall provide written notice of intent to claim an affirmative
1048     defense under this Subsection (12) as soon as practicable, but not later than 10 days before

1049     trial.
1050          (ii) The notice shall include the specific claims of the affirmative defense.
1051          (iii) The court may waive the notice requirement in the interest of justice for good
1052     cause shown, if the prosecutor is not unfairly prejudiced by the lack of timely notice.
1053          (d) The defendant shall establish the affirmative defense under this Subsection (12) by
1054     a preponderance of the evidence. If the defense is established, it is a complete defense to the
1055     charges.
1056          (13) (a) It is an affirmative defense that the person produced, possessed, or
1057     administered a controlled substance listed in Section 58-37-4.2 if the person was:
1058          (i) engaged in medical research; and
1059          (ii) a holder of a valid license to possess controlled substances under Section 58-37-6.
1060          (b) It is not a defense under Subsection (13)(a) that the person prescribed or dispensed
1061     a controlled substance listed in Section 58-37-4.2.
1062          (14) It is an affirmative defense that the person possessed, in the person's body, a
1063     controlled substance listed in Section 58-37-4.2 if:
1064          (a) the person was the subject of medical research conducted by a holder of a valid
1065     license to possess controlled substances under Section 58-37-6; and
1066          (b) the substance was administered to the person by the medical researcher.
1067          (15) The application of any increase in penalty under this section to a violation of
1068     Subsection (2)(a)(i) may not result in any greater penalty than a second degree felony. This
1069     Subsection (15) takes precedence over any conflicting provision of this section.
1070          (16) (a) It is an affirmative defense to an allegation of the commission of an offense
1071     listed in Subsection (16)(b) that the person:
1072          (i) reasonably believes that the person or another person is experiencing an overdose
1073     event due to the ingestion, injection, inhalation, or other introduction into the human body of a
1074     controlled substance or other substance;
1075          (ii) reports in good faith the overdose event to a medical provider, an emergency
1076     medical service provider as defined in Section 26-8a-102, a law enforcement officer, a 911
1077     emergency call system, or an emergency dispatch system, or the person is the subject of a
1078     report made under this Subsection (16);
1079          (iii) provides in the report under Subsection (16)(a)(ii) a functional description of the

1080     actual location of the overdose event that facilitates responding to the person experiencing the
1081     overdose event;
1082          (iv) remains at the location of the person experiencing the overdose event until a
1083     responding law enforcement officer or emergency medical service provider arrives, or remains
1084     at the medical care facility where the person experiencing an overdose event is located until a
1085     responding law enforcement officer arrives;
1086          (v) cooperates with the responding medical provider, emergency medical service
1087     provider, and law enforcement officer, including providing information regarding the person
1088     experiencing the overdose event and any substances the person may have injected, inhaled, or
1089     otherwise introduced into the person's body; and
1090          (vi) is alleged to have committed the offense in the same course of events from which
1091     the reported overdose arose.
1092          (b) The offenses referred to in Subsection (16)(a) are:
1093          (i) the possession or use of less than 16 ounces of marijuana;
1094          (ii) the possession or use of a scheduled or listed controlled substance other than
1095     marijuana; and
1096          (iii) any violation of Chapter 37a, Utah Drug Paraphernalia Act, or Chapter 37b,
1097     Imitation Controlled Substances Act.
1098          (c) As used in this Subsection (16) and in Section 76-3-203.11, "good faith" does not
1099     include seeking medical assistance under this section during the course of a law enforcement
1100     agency's execution of a search warrant, execution of an arrest warrant, or other lawful search.
1101          (17) If any provision of this chapter, or the application of any provision to any person
1102     or circumstances, is held invalid, the remainder of this chapter shall be given effect without the
1103     invalid provision or application.
1104          (18) A legislative body of a political subdivision may not enact an ordinance that is
1105     less restrictive than any provision of this chapter.
1106          (19) If a minor who is under 18 years of age is found by a court to have violated this
1107     section, the court may order the minor to complete:
1108          (a) a screening as defined in Section 41-6a-501;
1109          (b) an assessment as defined in Section 41-6a-501 if the screening indicates an
1110     assessment to be appropriate; and

1111          (c) an educational series as defined in Section 41-6a-501 or substance use disorder
1112     treatment as indicated by an assessment.
1113          Section 10. Effective date.
1114          If approved by two-thirds of all the members elected to each house, this bill takes effect
1115     upon approval by the governor, or the day following the constitutional time limit of Utah
1116     Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,
1117     the date of veto override.
1118          Section 11. Coordinating H.B. 425 with S.B. 121 -- Substantive and technical
1119     amendments.
1120          If this H.B. 425 and S.B. 121, Medical Cannabis Amendments, both pass and become
1121     law, it is the intent of the Legislature that the Office of Legislative Research and General
1122     Counsel shall prepare the Utah Code database for publication as follows:
1123          (1) the amendments to Subsection 4-41a-102(2) in this bill supersede the amendments
1124     to Subsection 4-41a-102(2) in S.B. 121;
1125          (2) the amendments to Subsection 4-41a-201(8) in this bill supersede the amendments
1126     to Subsection 4-41a-201(8) in S.B. 121;
1127          (3) the amendments to Section 26-61a-102 regarding the definition of "legal dosage
1128     limit" in this bill supersede the amendments to Section 26-61a-201 regarding the definition of
1129     "legal dosage limit" in S.B. 121;
1130          (4) the amendments to Subsection 26-61a-301(5) in this bill supersede the amendments
1131     to Subsection 26-61a-301(5) in S.B. 121; and
1132          (5) the amendments to Section 58-37-8 in this bill supersede the amendments to
1133     Section 58-37-8 in S.B. 121.